

# G Brandon Gunn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1531556/publications.pdf>

Version: 2024-02-01

190  
papers

6,520  
citations

71061

41  
h-index

95218

68  
g-index

198  
all docs

198  
docs citations

198  
times ranked

7457  
citing authors

#	ARTICLE	IF	CITATIONS
1	Late dysphagia after radiotherapy-based treatment of head and neck cancer. <i>Cancer</i> , 2012, 118, 5793-5799.	2.0	284
2	Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 782.	3.4	185
3	Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. <i>JAMA Oncology</i> , 2020, 6, 1397.	3.4	183
4	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis. <i>Radiotherapy and Oncology</i> , 2016, 120, 48-55.	0.3	177
5	Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i>BRAF</i> <sup>V600E</sup> -Mutated Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2019, 29, 1036-1043.	2.4	156
6	Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. , 2018, 6, 68.		148
7	Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 846-853.	0.4	128
8	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 30-41.	0.4	123
9	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1107-1114.	0.4	121
10	Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2017, 27, 672-681.	2.4	111
11	Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2018, 28, 945-951.	2.4	111
12	Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. <i>Cancer</i> , 2014, 120, 1975-1984.	2.0	106
13	Prospective randomized double-blind study of atlas-based organ-at-risk autosegmentation-assisted radiation planning in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 321-325.	0.3	96
14	Investigation of radiomic signatures for local recurrence using primary tumor texture analysis in oropharyngeal head and neck cancer patients. <i>Scientific Reports</i> , 2018, 8, 1524.	1.6	95
15	Unilateral Radiotherapy for the Treatment of Tonsil Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 204-209.	0.4	94
16	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 360-367.	0.4	88
17	Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 304-314.	0.3	85
18	Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. <i>Journal of Oncology Practice</i> , 2016, 12, 511-518.	2.5	81

#	ARTICLE	IF	CITATIONS
19	Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. <i>Radiotherapy and Oncology</i> , 2016, 121, 381-386.	0.3	78
20	Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy. <i>International Journal of Particle Therapy</i> , 2015, 2, 19-28.	0.9	76
21	Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 401-405.	0.3	73
22	Effect of Radiotherapy and Chemotherapy on the Risk of Mucositis During Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 235-242.	0.4	72
23	Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. <i>Radiotherapy and Oncology</i> , 2017, 124, 232-239.	0.3	69
24	Patterns of Locoregional Failure After Exclusive IMRT for Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 737-746.	0.4	67
25	Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. <i>Medical Dosimetry</i> , 2016, 41, 189-194.	0.4	62
26	Weekly Dose-Volume Parameters of Mucosa and Constrictor Muscles Predict the Use of Percutaneous Endoscopic Gastrostomy During Exclusive Intensity-Modulated Radiotherapy for Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 52-59.	0.4	61
27	Quality Assurance Assessment of Diagnostic and Radiation Therapy- Simulation CT Image Registration for Head and Neck Radiation Therapy: Anatomic Region of Interest-based Comparison of Rigid and Deformable Algorithms. <i>Radiology</i> , 2015, 274, 752-763.	3.6	58
28	Outcomes for olfactory neuroblastoma treated with induction chemotherapy. <i>Head and Neck</i> , 2017, 39, 1671-1679.	0.9	57
29	Late radiation-associated dysphagia (late-RAD) with lower cranial neuropathy after oropharyngeal radiotherapy: A preliminary dosimetric comparison. <i>Oral Oncology</i> , 2014, 50, 746-752.	0.8	56
30	The symptom burden of treatment-naïve patients with head and neck cancer. <i>Cancer</i> , 2015, 121, 766-773.	2.0	56
31	Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 1653-1661.	2.0	55
32	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 111, 281-288.	0.3	54
33	Prospective Qualitative and Quantitative Analysis of Real-Time Peer Review Quality Assurance Rounds Incorporating Direct Physical Examination for Head and Neck Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 532-540.	0.4	54
34	Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study. <i>NMR in Biomedicine</i> , 2015, 28, 1645-1654.	1.6	51
35	Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 1053.	1.2	51
36	Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy. <i>Scientific Data</i> , 2018, 5, 180173.	2.4	51

#	ARTICLE	IF	CITATIONS
37	The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. <i>Cancer</i> , 2013, 119, 3162-3169.	2.0	49
38	A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 344-352.	0.4	49
39	High symptom burden prior to radiation therapy for head and neck cancer: A patient-reported outcomes study. <i>Head and Neck</i> , 2013, 35, 1490-1498.	0.9	48
40	The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 724-733.	0.4	47
41	Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 700-708.	0.4	46
42	The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. <i>Practical Radiation Oncology</i> , 2016, 6, 241-247.	1.1	41
43	Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2018, 13, 19-23.	0.9	41
44	Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1244.	1.2	39
45	Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. <i>Quality of Life Research</i> , 2013, 22, 2331-2339.	1.5	38
46	Symptom burden as a driver of decisional regret in long-term oropharyngeal carcinoma survivors. <i>Head and Neck</i> , 2017, 39, 2151-2158.	0.9	38
47	Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. <i>Head and Neck</i> , 2020, 42, 1194-1201.	0.9	38
48	Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 842-848.	1.1	37
49	Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. <i>Head and Neck</i> , 2016, 38, E1472-80.	0.9	36
50	Conformal Radiotherapy of the Dominant Liver Metastasis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 562-567.	0.6	35
51	Methodology for analysis and reporting patterns of failure in the Era of IMRT: head and neck cancer applications. <i>Radiation Oncology</i> , 2016, 11, 95.	1.2	34
52	Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. <i>Head and Neck</i> , 2016, 38, 1739-1751.	0.9	33
53	Dynamic contrast-enhanced MRI detects acute radiotherapy-induced alterations in mandibular microvasculature: prospective assessment of imaging biomarkers of normal tissue injury. <i>Scientific Reports</i> , 2016, 6, 29864.	1.6	33
54	Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. <i>Head and Neck</i> , 2016, 38, E452-8.	0.9	32

#	ARTICLE	IF	CITATIONS
55	Improved setup and positioning accuracy using a three-point customized cushion/mask/bite-block immobilization system for stereotactic reirradiation of head and neck cancer. <i>Journal of Applied Clinical Medical Physics</i> , 2016, 17, 180-189.	0.8	32
56	Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions. <i>Radiotherapy and Oncology</i> , 2017, 124, 248-255.	0.3	32
57	Design and fabrication of a 3D-printed oral stent for head and neck radiotherapy from routine diagnostic imaging. <i>3D Printing in Medicine</i> , 2017, 3, 12.	1.7	31
58	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. <i>Npj Precision Oncology</i> , 2019, 3, 22.	2.3	31
59	Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2020, 20, 912.	1.1	31
60	Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. <i>Head and Neck</i> , 2012, 34, 1255-1262.	0.9	30
61	Creating customized oral stents for head and neck radiotherapy using 3D scanning and printing. <i>Radiation Oncology</i> , 2019, 14, 148.	1.2	30
62	Quantitative body mass characterization before and after head and neck cancer radiotherapy: A challenge of height-weight formulae using computed tomography measurement. <i>Oral Oncology</i> , 2016, 61, 62-69.	0.8	29
63	Effects of radiation on the temporal bone in patients with head and neck cancer. <i>Head and Neck</i> , 2016, 38, 1428-1435.	0.9	29
64	Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. <i>Head and Neck</i> , 2016, 38, E1459-66.	0.9	28
65	Conditional Survival Analysis of Patients With Locally Advanced Laryngeal Cancer: Construction of a Dynamic Risk Model and Clinical Nomogram. <i>Scientific Reports</i> , 2017, 7, 43928.	1.6	28
66	Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. <i>Radiotherapy and Oncology</i> , 2018, 128, 442-451.	0.3	28
67	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. <i>Cancer</i> , 2019, 125, 1823-1829.	2.0	28
68	Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2014, 120, 3082-3088.	2.0	27
69	Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose adaptation for human papillomavirus positive oropharyngeal cancer patients compared with standard IMRT. <i>Clinical and Translational Radiation Oncology</i> , 2018, 11, 11-18.	0.9	27
70	Symptom burden and dysphagia associated with osteoradionecrosis in long-term oropharynx cancer survivors: A cohort analysis. <i>Oral Oncology</i> , 2017, 66, 75-80.	0.8	26
71	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. <i>Seminars in Radiation Oncology</i> , 2018, 28, 108-113.	1.0	26
72	Late radiation-associated dysphagia with lower cranial neuropathy in long-term oropharyngeal cancer survivors: Video case reports. <i>Head and Neck</i> , 2015, 37, E56-62.	0.9	25

#	ARTICLE	IF	CITATIONS
73	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old. <i>Radiation Oncology</i> , 2017, 12, 150.	1.2	25
74	Patient-reported outcomes of symptom burden in patients receiving surgical or nonsurgical treatment for low-intermediate risk oropharyngeal squamous cell carcinoma: A comparative analysis of a prospective registry. <i>Oral Oncology</i> , 2019, 91, 13-20.	0.8	25
75	Outcomes of carotid-sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. <i>Laryngoscope</i> , 2020, 130, 146-153.	1.1	25
76	Chronic radiation-associated dysphagia in oropharyngeal cancer survivors: Towards age-adjusted dose constraints for deglutitive muscles. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 16-22.	0.9	24
77	Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. <i>Clinical and Translational Radiation Oncology</i> , 2019, 18, 120-127.	0.9	24
78	Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 1066.	1.2	23
79	Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer. <i>Chinese Clinical Oncology</i> , 2016, 5, 54-54.	0.4	23
80	Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. <i>Head and Neck</i> , 2017, 39, 1291-1295.	0.9	22
81	Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2021, 31, 1235-1243.	2.4	22
82	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. <i>Radiotherapy and Oncology</i> , 2015, 117, 132-138.	0.3	21
83	Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose-response characterization of quantitative signal kinetics. <i>Radiotherapy and Oncology</i> , 2016, 118, 315-322.	0.3	21
84	Single-item discrimination of quality of life altering dysphagia among 714 long-term oropharyngeal cancer survivors: Comparison of patient-reported outcome measures of swallowing. <i>Cancer</i> , 2019, 125, 1654-1664.	2.0	21
85	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. <i>Radiotherapy and Oncology</i> , 2020, 142, 133-139.	0.3	21
86	Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. <i>Radiotherapy and Oncology</i> , 2020, 148, 258-266.	0.3	21
87	Prospective assessment of an atlas-based intervention combined with real-time software feedback in contouring lymph node levels and organs-at-risk in the head and neck: Quantitative assessment of conformance to expert delineation. <i>Practical Radiation Oncology</i> , 2013, 3, 186-193.	1.1	20
88	Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 148, 252-257.	0.3	20
89	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. <i>Radiotherapy and Oncology</i> , 2018, 126, 75-80.	0.3	19
90	Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. <i>Cancer</i> , 2019, 125, 1536-1546.	2.0	19



#	ARTICLE	IF	CITATIONS
91	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, 619-626.	1.1	18
92	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. <i>Head and Neck</i> , 2017, 39, 1609-1620.	0.9	18
93	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 28-35.	0.9	18
94	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. <i>Cancer</i> , 2018, 124, 1415-1427.	2.0	18
95	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1029-1035.	0.4	18
96	Modeling symptom drivers of oral intake in long-term head and neck cancer survivors. <i>Supportive Care in Cancer</i> , 2019, 27, 1405-1415.	1.0	18
97	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 145, 95-100.	0.3	18
98	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. <i>Radiotherapy and Oncology</i> , 2021, 160, 32-39.	0.3	18
99	Recent advances and emerging therapies in anaplastic thyroid carcinoma. <i>F1000Research</i> , 2018, 7, 87.	0.8	18
100	Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 426-436.	0.4	18
101	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 1702-1707.	2.0	17
102	Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. <i>International Journal of Cancer</i> , 2016, 138, 1290-1297.	2.3	17
103	Long-term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies. <i>Laryngoscope</i> , 2020, 130, 86-93.	1.1	17
104	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. <i>British Journal of Cancer</i> , 2021, 124, 628-633.	2.9	17
105	Self-Reported Trismus: prevalence, severity and impact on quality of life in oropharyngeal cancer survivorship: a cross-sectional survey report from a comprehensive cancer center. <i>Supportive Care in Cancer</i> , 2021, 29, 1825-1835.	1.0	17
106	A prospective in silico analysis of interdisciplinary and interobserver spatial variability in post-operative target delineation of high-risk oral cavity cancers: Does physician specialty matter?. <i>Clinical and Translational Radiation Oncology</i> , 2018, 12, 40-46.	0.9	16
107	Quantifying the accuracy of deformable image registration for cone-beam computed tomography with a physical phantom. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 92-100.	0.8	16
108	Fatigue following radiation therapy in nasopharyngeal cancer survivors: A dosimetric analysis incorporating patient report and observer rating. <i>Radiotherapy and Oncology</i> , 2019, 133, 35-42.	0.3	16

#	ARTICLE	IF	CITATIONS
109	Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. <i>International Journal of Particle Therapy</i> , 2016, 2, 533-543.	0.9	16
110	Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 221-233.	0.4	15
111	Decreased gastrostomy tube incidence and weight loss after transoral robotic surgery for low- to intermediate-risk oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2018, 40, 2507-2513.	0.9	15
112	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching liquid biopsy and quantitative tumor modeling. <i>BMC Cancer</i> , 2018, 18, 903.	1.1	14
113	A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. <i>Radiotherapy and Oncology</i> , 2019, 130, 46-55.	0.3	14
114	Radiation-Induced Hypothyroidism After Radical Intensity Modulated Radiation Therapy for Oropharyngeal Carcinoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 111-119.	0.6	14
115	Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors. <i>Cancer</i> , 2021, 127, 4470-4480.	2.0	14
116	Estimation of daily interfractional larynx residual setup error after isocentric alignment for head and neck radiotherapy: quality assurance implications for target volume and organs-at-risk margination using daily CT on-rails imaging. <i>Journal of Applied Clinical Medical Physics</i> , 2015, 16, 159-169.	0.8	13
117	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. <i>Oral Oncology</i> , 2015, 51, 195-201.	0.8	13
118	Evaluation of the accuracy of deformable image registration on MRI with a physical phantom. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 166-173.	0.8	13
119	A Phase I/II Study of Altered Fractionated IMRT Alone for Intermediate T-Stage Oropharyngeal Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 489-495.	1.0	12
120	Characterization of a new physical phantom for testing rigid and deformable image registration. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 145-153.	0.8	12
121	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. <i>Supportive Care in Cancer</i> , 2020, 28, 261-269.	1.0	12
122	Estimating PTV Margins in Head and Neck Stereotactic Ablative Radiation Therapy (SABR) Through Target Site Analysis of Positioning and Intrafractional Accuracy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 185-193.	0.4	12
123	Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. <i>Advances in Radiation Oncology</i> , 2020, 5, 567-572.	0.6	12
124	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. <i>Oral Oncology</i> , 2021, 113, 105125.	0.8	12
125	Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 159, 21-27.	0.3	12
126	Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 146, 200-204.	0.3	12



#	ARTICLE	IF	CITATIONS
127	The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 71-78.	0.9	11
128	Outcomes after radiation therapy for <scp>T2N0</scp>/stage <scp>II</scp> glottic squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 2791-2800.	0.9	11
129	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 148, 133-139.	0.3	11
130	Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. <i>Current Treatment Options in Oncology</i> , 2021, 22, 54.	1.3	11
131	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 319-327.	0.9	11
132	Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1496-1504.	0.4	11
133	Orbital carcinomas treated with adjuvant intensity-modulated radiation therapy. <i>Head and Neck</i> , 2016, 38, E580-7.	0.9	10
134	The First Reported Case of Primary Intestinal-type Adenocarcinoma of the Middle Ear and Review of the Literature. <i>Otology and Neurotology</i> , 2017, 38, e364-e368.	0.7	10
135	Outcomes and patterns of radiation associated brain image changes after proton therapy for head and neck skull base cancers. <i>Radiotherapy and Oncology</i> , 2020, 151, 119-125.	0.3	10
136	Osteoradionecrosis in patients with salivary gland malignancies. <i>Oral Oncology</i> , 2016, 57, 1-5.	0.8	9
137	Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 14, 1-5.	1.2	9
138	Non-English language validation of patient-reported outcome measures in cancer clinical trials. <i>Supportive Care in Cancer</i> , 2020, 28, 2503-2505.	1.0	9
139	Role of induction chemotherapy for oral cavity squamous cell carcinoma. <i>Cancer</i> , 2021, 127, 3107-3112.	2.0	9
140	Advances in Radiation Oncology for the Management of Oropharyngeal Tumors. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, 629-643.	0.5	8
141	The role of salvage surgery with interstitial brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers. <i>Cancers of the Head &amp; Neck</i> , 2019, 4, 4.	6.2	8
142	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. <i>Cancer</i> , 2020, 126, 749-756.	2.0	8
143	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. <i>Advances in Radiation Oncology</i> , 2020, 5, 929-935.	0.6	8
144	Computed Tomography Radiomics Kinetics as Early Imaging Correlates of Osteoradionecrosis in Oropharyngeal Cancer Patients. <i>Frontiers in Artificial Intelligence</i> , 2021, 4, 618469.	2.0	8

#	ARTICLE	IF	CITATIONS
145	Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. <i>International Journal of Particle Therapy</i> , 2021, 8, 108-118.	0.9	8
146	Nasopharyngeal Carcinoma Metastasis to the Pituitary Gland: A Case Report and Literature Review. <i>Journal of Neuro-Oncology</i> , 2004, 68, 87-90.	1.4	7
147	CT-based volumetric tumor growth velocity: A novel imaging prognostic indicator in oropharyngeal cancer patients receiving radiotherapy. <i>Oral Oncology</i> , 2016, 63, 16-22.	0.8	7
148	Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2020, 81, 638-644.	0.4	7
149	A Dosimetric Comparison of Oral Cavity Sparing in the Unilateral Treatment of Early Stage Tonsil Cancer: IMRT, IMPT, and Tongue-Deviating Oral Stents. <i>Advances in Radiation Oncology</i> , 2020, 5, 1359-1363.	0.6	7
150	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. <i>Oral Oncology</i> , 2018, 79, 1-8.	0.8	6
151	Stereotactic radiosurgery for trigeminal pain secondary to recurrent malignant skull base tumors. <i>Journal of Neurosurgery</i> , 2019, 130, 812-821.	0.9	6
152	Transitioning from measurement-based to combined patient-specific quality assurance for intensity-modulated proton therapy. <i>British Journal of Radiology</i> , 2020, 93, 20190669.	1.0	6
153	Strategic Operational Redesign for Successfully Navigating Prior Authorization Barriers at a Large-Volume Proton Therapy Center. <i>JCO Oncology Practice</i> , 2020, 16, e1067-e1077.	1.4	6
154	A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods. <i>Oral Oncology</i> , 2020, 106, 104665.	0.8	6
155	Data from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumors. <i>Scientific Data</i> , 2020, 7, 63.	2.4	6
156	<sup>18</sup> F-FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 29, 93-101.	0.9	6
157	Unilateral Radiotherapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papilloma Virus (HPV), Positron-emission Tomography (PET) and Intensity-modulated Radiation Therapy (IMRT). <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	6
158	Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. <i>Head and Neck</i> , 2014, 36, 819-825.	0.9	5
159	Cognitive function and patient-reported memory problems after radiotherapy for cancers at the skull base: A cross-sectional survivorship study using the Telephone Interview for Cognitive Status and the MD Anderson Symptom Inventory-Head and Neck Module. <i>Head and Neck</i> , 2017, 39, 2048-2056.	0.9	5
160	Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 98-105.	0.9	5
161	Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 615.	1.2	5
162	Severe radiation therapy-related soft tissue toxicity in a patient with porphyria cutanea tarda: A literature review. <i>Head and Neck</i> , 2010, 32, 1112-1117.	0.9	4

#	ARTICLE	IF	CITATIONS
163	Improved human observer performance in digital reconstructed radiograph verification in head and neck cancer radiotherapy. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2015, 10, 1667-1673.	1.7	4
164	Development and validation of a contouring guideline for the taste bud bearing tongue mucosa. <i>Radiotherapy and Oncology</i> , 2021, 157, 63-69.	0.3	4
165	Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. <i>International Journal of Particle Therapy</i> , 2021, 8, 261-272.	0.9	4
166	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. <i>International Journal of Particle Therapy</i> , 2021, 8, 234-247.	0.9	4
167	Proton Radiotherapy to Reduce Late Complications in Childhood Head and Neck Cancers. <i>International Journal of Particle Therapy</i> , 2021, 8, 155-167.	0.9	4
168	Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 374-382.	0.9	4
169	Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
170	Evaluation of the high definition field of view option of a large-bore computed tomography scanner for radiation therapy simulation. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 13, 44-49.	1.2	3
171	SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. <i>Practical Radiation Oncology</i> , 2020, 10, 363-371.	1.1	3
172	Combination Intensity Modulated Proton Therapy and Passive Scatter Boost for Rapidly Progressing Nasal Cavity Squamous Cell Carcinoma. <i>Cureus</i> , 2017, 9, e1685.	0.2	3
173	Proton Therapy in a Pandemic: An Operational Response to the COVID-19 Crisis. <i>International Journal of Particle Therapy</i> , 2020, 7, 54-57.	0.9	3
174	Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors. <i>Cancer Medicine</i> , 0, , .	1.3	3
175	Complications of tympanostomy tubes in head and neck cancer patients. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2016, 37, 356-361.	0.6	2
176	Optimizing laryngeal sparing with intensity modulated radiotherapy or volumetric modulated arc therapy for unilateral tonsil cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 10, 29-34.	1.2	2
177	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. <i>Cancer</i> , 2021, 127, 1228-1237.	2.0	2
178	Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 213-222.	0.9	2
179	Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 805-813.	2.3	2
180	Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module. <i>Balkan Medical Journal</i> , 2016, 33, 339-343.	0.3	2

#	ARTICLE	IF	CITATIONS
181	Linguistic validation of the Greek M.D. Anderson Symptom Inventory - Head and Neck Module. , 2012, 3, 29-31.		2
182	Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Scientific Reports, 2022, 12, 6662.	1.6	2
183	In Regard to Kjems etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 96, 240.	0.4	1
184	Reply to radiotherapy for human papillomavirusâ€positive oropharyngeal cancers in the National Cancer Data Base. Cancer, 2016, 122, 3411-3412.	2.0	1
185	Feeding Tube Utilization in Patients with Salivary Gland Malignancies. Otolaryngology - Head and Neck Surgery, 2017, 156, 109-117.	1.1	1
186	Factors associated with complex oral treatment device usage in patients with head and neck cancer. Clinical and Translational Radiation Oncology, 2021, 30, 78-83.	0.9	1
187	The influence of radiation dose on taste impairment in a prospective observational study cohort of oropharyngeal cancer patients. Acta OncolÃ³gica, 2022, 61, 146-152.	0.8	1
188	Analysis of Charges Associated with Definitive Nonsurgical Therapy for Early-Stage Lateralized Tonsil Cancer. Annals of Surgical Oncology, 2015, 22, 2755-2760.	0.7	0
189	Radiotherapy for Temporal Bone Cancers. , 2018, , 363-378.		0
190	Postoperative Intensity-Modulated Radiation Therapy for Head and Neck Cancers: A Case-Based Review. , 2015, , 193-213.		0